No significant safety or dose limiting toxicities reported PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results Several patients in the first and second cohort remain on ...
Follows Safety Review Committee (SRC) approval based on safety data from patients in Cohorts 1 and 2 No significant safety or dose limiting toxicities reported in Cohorts 1 and 2 PK data from Cohorts ...
Beyond terms like "met endpoint" or "statistically significant," understanding how to read clinical trial results and what ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results